Company intelligence / Profile preview

CISTIM

Leuven, Flanders, Belgium

Ownership: Private
Employees: ~45
Development stage: Preclinical

Overview

CISTIM specializes in early-stage drug discovery—validating novel biological concepts from academia or biotech partners and advancing them to preclinical candidate stage. It collaborates closely with CD3 to deliver potential new medicines addressing critical medical needs. No clinical results are available as the company operates at the preclinical/early development stage.

Modalities: Small moleculeBiologicMonoclonal antibody
Industry: Academic Hospital/University/Research

Partnerships

Centre for Drug Design and Discovery (CD3)SandboxAQ (for Parkinson’s disease therapeutics development)KU Leuven Lab of Cellular Transport SystemsOpen Philanthropy (for influenza pandemic preparedness)

Beyond the preview

Go deeper on CISTIM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CISTIM.

Explore the full profile